Wissenschaftliche Neuigkeiten

Image
BIOTRONIK Wissenschaftliche Meldungen
BIOTRONIKs neueste wissenschaftliche Beiträge
greyblue
top_right
On
greyblue
l

BIOTRONIKs neueste wissenschaftliche Beiträge

KONGRESSE UND PUBLIKATIONEN

Neuigkeiten von BIOTRONIK für Fachkreise

Hier finden Vertreter medizinischer Fachredaktionen und Fachjournalisten wissenschaftliche Beiträge. Zudem finden Sie Neuigkeiten und Zusammenfassungen aktueller Erkenntnisse der Medizintechnik, die von BIOTRONIK auf internationalen kardiologischen Fachkongressen vorgestellt worden sind. Unsere wissenschaftlichen Beiträge sind derzeit nur in englischer Sprache veröffentlicht.

Zara Barlas

Corporate Public Relations & Communications

press@biotronik.com

+49 (0) 30 68905 1414


What's NEW at BIOTRONIK

For the 12th straight year, Expert Meeting Berlin (EMB) was committed to the sharing of best practice between cardiologists and electrophysiologists from around the globe.Physicians gathered in Berlin to share their practical expertise, latest insights into new device technologies and forge scientific relationships during the two-day meeting. EMB 2019 featured topics included recent scientific developments in ventricular and atrial arrhythmia management, including patient-tailored heart failure (HF) therapy concepts and evolving eHealth solutions for multidisciplinary care. Further, this year’s EMB had a special focus on digital health applications and advantages through artificial intelligence in medicine.

Kevin Campbell speaking at EMB 2019

Dr. med. Christopher Piorkowski

What's NEW at BIOTRONIK

Individualized Therapy Concepts at the Heart of Discussions at the 10th Expert Meeting BerlinMore than 240 rhythm specialists from 30 different countries attended the 10th Expert Meeting Berlin (EMB), with talks strongly focused on individualizing therapy for patients suffering from atrial fibrillation and chronic heart failure.The year’s meeting offered a platform for exchange on topics ranging from the techniques of ablation therapy for ventricular tachycardia to heart failure therapy tailored to individual patient needs. Amidst discussions about the treatment of atrial fibrillation, many speakers concurred that an individualized approach offered safer and more effective management of patients’ unique conditions, while some speakers also expressed support for a more cross-disciplinary approach to care. Attendees also discussed novel technologies for assessment and monitoring, including 3D mapping systems, substrate-based imaging and remote monitoring for cardiac implants, offering a glimpse into how new technologies are revolutionizing therapy.


Final TRUECOIN conclusions from ESC 2016

What's NEW at BIOTRONIK

Home Monitoring Proven to Reduce Risk of All-Cause Mortality for All Types of ICD PatientsDr. Gerhard Hindricks, Heart Center Leipzig, presented results from TRUECOIN trial in which Home Monitoring demonstrated to reduce all-cause mortality across all ICD indications by 38%.The TRUECOIN study pools 2,405 patients from the TRUST1, ECOST2 and IN-TIME3 trials.Results came days after REM-HF and MORE-CARE studies—which looked at competitor systems but NOT the BIOTRONIK Home Monitoring system—showed no safety or mortality benefit for remote monitoring of ICD patients.


EPIC Alliance at ESC 2016

Scientific Symposium Focuses on CRT and AF Ablation Non-RespondersAt a packed ESC Scientific Symposium an all-women panel of experts from EPIC Alliance presented original research and real-world clinical evidence on non-responders to cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) ablation.For reasons largely unknown, the success rates of both CRT and AF ablation procedures plateau at about 70 percent.4 Ongoing studies such as BIOWOMEN are investigating which patients best respond to CRT therapy, and the EPIC event shone a rare light on the important subject.


Cardiostim Innovation Awar

What's NEW at BIOTRONIK

BIOTRONIK Wins Cardiostim Innovation Award for Best Practice Improvement with MRI AutoDetect FeatureBIOTRONIK won the Cardiostim Innovation Award in the category “Best Practice Improvement” for its MRI AutoDetect feature. The company’s Ilivia implantable cardioverter defibrillators (ICDs) and cardiac resynchronization device (CRT-Ds) are the world’s first equipped with a sensor capable of automatically recognizing a magnetic resonance imaging (MRI) environment.


Niraj Varma

Growing Importance of Remote Monitoring and Potential for New Heart Monitor Indications Detailed at Cardiostim Scientific SessionBIOTRONIK Home Monitoring® received strong endorsements during the Cardiostim scientific session “Improving Patient Outcomes in Arrhythmia Management.” Experts also highlighted how new indications for insertable cardiac monitors could expand patient care.


Dr. Laura Vitali Serdoz

Physicians Present at Cardiostim Conference´s All-Women Panel: Hot Topics in CRMPhysicians presented original research and real-world clinical evidence at a symposium organized by the EPIC Alliance, an initiative to promote women in the field of electrophysiology at the Cardiostim 2016 conference. They spoke about remote monitoring, CRT guidelines, ICD programming and new approaches to defibrillation and pacing during the EPIC Alliance symposium “Hear the Experts: Contemporary Issues in Cardiac Rhythm Management.”


BIOTRONIK Magmaris

What's NEW at BIOTRONIK

Magmaris, the First Clinically Proven Bioresorbable Magnesium Scaffold, Shows Long-Term Safety in BIOSOLVE-II Trial12 month data from the BIOSOLVE-II trial were presented during a Hotline Session at EuroPCR 2016. The study established the safety and clinical performance of Magmaris, the world’s first clinically proven magnesium-based sirolimus eluting bioresorbable scaffold. Full one year data from the prospective, international first-in-human trial has been published in The European Heart Journal concurrently with the Hotline Session. The 12 month results demonstrated no incidence of scaffold thrombosis and a low rate of target lesion failure.


BIOTRONIK Pantera Lux

Pantera Lux Drug-Coated Balloon Proves Non-Inferior to Drug-Eluting StentThe BIOLUX RCT study was presented at EuroPCR 2016. The trial compared the Pantera Lux drug-coated balloon (DCB) to a latest generation sirolimus-eluting stent (DES) in treatment of in-stent restenosis, the main indication for DCB. Study investigators found that Pantera Lux is angiographically non-inferior to stenting with the latest generation DES at six months.


BIOTRONIK hybrid drug-eluting stent Orsiro

Compelling Efficacy and Safety Data for Orsiro Hybrid Drug-Eluting Stent Presented during EuroPCR Hotline SessionBIOTRONIK presented results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Resolute Integrity DES were presented during a Hotline Session at EuroPCR 2016. The multicenter, randomized, controlled all-comers ORIENT trial enrolled 372 patients who received either Orsiro or Resolute Integrity in treatment of a wide variety of coronary heart disease.


Passeo-18 Lux

What's NEW at BIOTRONIK

Studies Highlight Efficacy of BIOTRONIK Passeo-18 Lux Drug-Coated Balloon in Superficial Femoral Artery DiseaseNew data regarding the Passeo-18 Lux drug-coated balloon (DCB) were presented during a scientific symposium at LINC 2016. During the symposium, which focused on data emerging from Passeo-18 Lux’s rigorous clinical program, interim six-month data from the BIOLUX P-III registry was released for the first time. The prospective multicenter all-comers study is designed to provide further evidence for Passeo-18 Lux’s efficacy in treating peripheral artery disease in routine clinical practice; it is enrolling a minimum of 700 patients at 55 sites in 19 countries in Europe, Asia, Australia and the Pacific.


Please contact us if you require further information

Zara Barlas

Corporate Public Relations & Communications

press@biotronik.com

+49 (0) 30 68905 1414